2019 SUMMIT SPEAKERS
THOMAS FUCHS Founder and Chief Scientific Officer, Paige
Professor Dr. Thomas J. Fuchs is the Founder and Chief Scientific Officer at Paige, the leader in computational pathology focused on building artificial intelligence (AI) to transform the clinical diagnosis and treatment of cancer. Additionally, he is an Associate Professor for Machine Learning at Weill-Cornell University, and a director of the Warren Alpert Center for Digital and Computational Pathology at Memorial Sloan Kettering Cancer Center in New York City.
MIA DAND CEO, Lighthouse3
Mia Dand is a digital transformation leader and passionate diversity in tech advocate with extensive experience in building human-centric programs at global companies like Google, HP, eBay, Symantec and others. As the CEO of Lighthouse3, an emerging tech research and advisory firm based in Oakland, California, Mia guides large enterprises on responsible adoption of new technologies like Artificial Intelligence with special emphasis on critical areas like ethics, governance, and regulatory compliance.
Mia is the author of “100 Brilliant Women in AI Ethics”, a definitive guide to help conference organizers and brands recruit more talented women in this space. She is also the organizer for SF AI, Berkeley AI, & SF AR/VR meetup groups with over 3.5K members in the San Francisco Bay Area and hosts monthly AI Ethics chats on Twitter (@MiaD)
Dr. Bruce Lamb received a BA degree in Biology from Swarthmore College, his PhD in Molecular Biology from the University of Pennsylvania and a post-doctoral fellowship at Johns Hopkins University. In 1996, Dr. Lamb was recruited to Case Western Reserve University, where he rose from Assistant to Associate Professor and finally moved to the Cleveland Clinic in 2005. At the Cleveland Clinic, Dr. Lamb was promoted from Associate Professor to Full Professor in 2011, and later was recruited to become the Executive Director of the Stark Neurosciences Research Institute with the IU School of Medicine in January 2016.
Dr. Lamb has received numerous awards and honors including the Jennifer B. Langston Award from the Cleveland Chapter of the Alzheimer’s Association, the National Civic Award, and the Zaven Khachaturian Lifetime Achievement Award from the National Alzheimer’s Association. He is a Fellow in the American Association for the Advancement of Science and a member (and Vice-Chair) of the Medical and Scientific Advisory Council of the National Alzheimer’s Association.
Dr. Lamb’s laboratory works on the basic science of Alzheimer’s disease, with a focus on: 1) genetic modifiers identified from both mouse and human studies, 2) microglia and neuronal-microglial communication in the development and progression of AD pathologies; and 3) traumatic brain injury as an environmental modifier for the development of AD pathologies. Dr. Lamb is also one of the lead PIs of the NIH-funded Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease (MODEL-AD) consortium. In addition, Dr. Lamb is actively involved in advocacy for increased research funding for the disease.
Clem McDonald, MD MD Chief Health Data Standards Officer, National Library of Medicine, National Institutes of Health
Dr. McDonald’s research focuses on clinical informatics; analyzing clinical data and providing feedback to clinicians; development and study of electronic medical record systems (EMRs) and personal health records (PHRs); automatic reminder systems; promoting the development, enhancement, and adoption of clinical messaging and vocabulary standards; and using huge clinical databases and de-identifying them for clinical research use.
He has led the development of the medical informatics standards necessary for transmitting patient data from source systems to electronic medical records and research databases. He was one of the founders of the Health Level 7 (HL7) message standards, used in all hospitals today, and he also developed the Logical Observation Identifier Names and Codes (LOINC) database of universal codes for clinical observations, including laboratory tests, clinical measurements and physician reports.
In 1972, Dr. McDonald developed one of the nation’s first electronic medical record systems (EMRs), the Regenstrief Medical Record System (RMRS), and directed its use in clinical trials that have illuminated the ways in which electronic records can improve patient care. He published the first randomized trials showing the benefits of computer reminder systems and of physician order entry systems. He has written more than 275 peer-reviewed articles. Additionally, he implemented the Indiana Network for Patient Care, the first community-wide health information exchange, which now carries over 4 billion clinical observations from more than 70 hospitals, and is considered a national model for regional health information exchange.
His work at NIH continues this trend. Dr. McDonald collaborates in numerous efforts to facilitate industry adoption of standard vocabularies in electronic medical records and public health reporting, as required by meaningful use regulations. He has been working with numerous NIH Institutes to align research terminology with federally mandated clinical terminologies. He emphasizes the need for using the same standards where information content overlaps between clinical and research domains (e.g. laboratory testing, vital signs, and clinical survey instruments) that can be integrated with existing clinical LOINC variables to allow data sharing and interoperability.
Dr. McDonald served as the Scientific Director of the Lister Hill National Center for Biomedical Communications at NLM from 2006-2018, overseeing all LHNCBC research and development in biomedical informatics related to consumer health, clinical data, image processing and visualization, and natural language processing. Current research projects include biomedical data visualization, high resolution electron microscopy, imaging tools for cancer research, and 3D biomedical imaging research, openI (medical citations enriched by relevant images with capacity to search by image), and automated medical text indexing research. Dr. McDonald currently serves as the NLM Chief Health Data Standards Officer.
Dr. McDonald obtained his medical degree from the University of Illinois, and completed his internship in Internal Medicine at Boston City Hospital, Harvard Medical Service, and his residency in Internal Medicine at Cook County Hospital and University of Wisconsin. Before beginning his residency, he earned an MS in Biomedical Engineering from Northwestern University, and completed a fellowship at NIH, where he managed the development of the first clinical laboratory computer system at the Clinical Research Center.
Prior to joining NLM, Dr. McDonald was Regenstrief Professor of Medical Informatics and Distinguished Professor of Medicine at the Indiana University (IU) School of Medicine and Director of the Regenstrief Institute for Health Care.
Dr. Liana G. Apostolova, joined the IU School of Medicine as a The Barbara and Peer Baekgaard Professor in Alzheimer’s Disease Research and Professor in Neurology, Radiology, Medical and Molecular Genetics at in June of 2015. Dr. Apostolova is a prolific researcher. Her research focuses on the early symptomatic and presymptomatic stages of Alzheimer’s Disease and on the development and validation of sensitive imaging and genetic biomarkers for Alzheimer’s disease and other dementing disorders. Dr. Apostolova is the recipient of many NIH and industry supported grants and several research awards. She is the principal investigator of the multimodal clinical and biomarker Longitudinal Early-Onset AD Study (LEADS, R56 and U01 AG057195) which will recruit, characterize and follow 400 patients with definite EOAD and 100 age-matched control subjects across 15 US clinical sites. She also directs the Clinical Core of the Alzheimer’s Disease Center at Indiana University. Dr. Apostolova has served as a research mentor to over 70 undergraduate, 23 graduate, and five post-graduate students, as well as nine junior faculty researchers to date. She serves as Editor for the Alzheimer’s and Dementia: Disease Assessment and Monitoring Journal. She graduated Summa Cum Laude from the Medical University, Sofia, Bulgaria in 1998, and completed Neurology residency training at University of Iowa and Dementia fellowship at UCLA.
Ron Alfa is Senior Vice President, Translational Discovery at Recursion (Recursion Pharmaceuticals), a technology-enabled drug discovery company combining machine learning with automated cell biology. At Recursion, his team manages commercial and translational strategy for Recursion’s portfolio. He received training in Medicine, as well as Neurosciences & Genetics at Stanford University where his work contributed to the discovery of new hormone signals in humans. He has also worked closely with entrepreneurs and start-ups at Stanford-affiliated accelerator, StartX. Ron’s passion is to bring new medicines to patients at a scale never before achieved.
ANDREA DE SOUZA Senior Director, Research Data Sciences & Engineering , Eli Lilly and Company
Andrea de Souza began her career as a neuroscience researcher and transitioned to building and leading informatics and scientific teams across multiple therapeutic areas. Most recently, de Souza focused on building the Pharma Artificial Intelligence market at NVIDIA. Through this experience she has travelled the world advising biopharmaceutical, academics, research institutes, and startups in the potential of machine learning and artificial intelligence across every discipline in our industry. Prior to her current role at NVIDIA, deSousa held leadership positions at the Broad Institute of Harvard and MIT, Amgen, and Roche.
Additionally, de Souza serves as an Informatics Advisor for the National Institute of Diabetes, Digestive and Kidney Diseases and is a member of the NIH HubMap Advisory Team. de Souza has a B.S. in Animal Physiology from UC Davis, a Master’s in Health Administration from University of San Francisco, and an MBA from MIT Sloan. Through her broad research efforts, de Souza has publications in journals as diverse as the Journal of Computer-Aided Molecular Design, Bio-organic & Medicinal Chemistry Letters, and Neuropharmacology.
de Souza currently works at Eli Lilly & Company, empowering the LRL Research organization with greater computational, analytics-intense experimentation to raise the innovation of our scientists. As the Global Head of Data Sciences and Advanced Analytics, de Souza leads four organizations: the High Performance Computing Team, the Data Engineering team, the AI/ML team for Research and the Research Informatics team.
RAMESH DURVASULA VP, Research IT, Eli Lilly and Company
As the Information Officer for Research, Ramesh Durvasula is responsible for the IT and informatics capabilities that accelerate the discovery and preclinical efforts of Lilly Research Labs. Ramesh has focused his career on the intersection of life science and data science. His mission at Lilly is to unite science with technology to accelerate R&D pipelines and deliver innovative therapeutics. Prior to Lilly, Ramesh was Executive Director of Discovery IT and Lab Automation at Bristol-Myers Squibb; over his 12 years at BMS, Ramesh focused on integrating both physical lab and digital analytics systems into seamless capabilities. Prior to BMS, Ramesh spent several years at Tripos, a computational chemistry software firm. He is an active leader in many industry forums, such as the Pistoia Alliance, the Allotrope Foundation, and the DOE Exascale Computing Project, and he is also a member of the Dean’s Advisory Council of Indiana University’s School of Informatics, Computing, and Engineering. Ramesh earned his BA in Chemistry and PhD in Biochemistry from the University of Virginia.
Tyler Foxworthy is a mathematician and data scientist working on a wide range of problems in industry. An alumnus of Purdue University, his research is largely focused on the development of high performance algorithms at the intersection of complex networks, machine learning, and natural language processing. He is the founder of R&D firm Vertex Intelligence, and is a scientific advisor, consultant, and investor. Foxworthy’s prior experience includes leadership and research roles in academia, medical device, management consulting, and SaaS. Additionally, Foxworthy maintains an active research program and is a regular speaker at international scientific and mathematics conferences including the Society of Industrial and Applied Mathematics and (SIAM).
KAREN MADDEN, PhD Vice President, Technology and Innovation, PerkinElmer
Karen is Vice President of Technology and Innovation and is responsible for helping drive innovation across all of PerkinElmer businesses and end markets, including diagnostics, life science, analytical and food. This includes driving collaboration internally and externally – including chairing PerkinElmer’s Technology & Innovation Council, establishing strategic partnerships, and using creative funding mechanisms. Karen is also responsible for identifying new markets, technologies, and innovative customer driven product offerings – including promotional internal idea generation, championing ideas that cross business, and infusing customer voice into PerkElmer’s innovation efforts.
Dr. Madden was formerly President of PerkinElmer’s Informatics business, a leading specialize software provider to the scientific research and development market. ParkinElmer Informatics isa. leader in electronic laboratory notebooks (ELN) and scientific desktop (ChemDraw) software, as well as analytics and visualization (Spotfire) in scientific research, development and manufacturing markets. Prior to serving as PResident of the Informatics business, Dr. Madden held various leadership and business development positions within PerkinElmer in the Diagnostic and Emerging Technologies businesses. Dr. Madden joined PerkinElmer in 2010 through an acquisition of VisEn, a molecular imaging company, where she served as Vice President of Business Development and Corporate Development.
Prior to joining VisEn, she was a Director at Feinstein Kean Healthcare and Kendall Strategies, leading business strategy and working with a range of clients from small start-ups to a multi-national biopharmaceutical companies conducting business strategy, due diligence, valuation analyses, and qualitative and quantitative market research. Dr. Madden holds a B.A. in Chemistry from Boston University and a M.S. from the University of Pennsylvania. She did her doctoral work in Chemistry at Rutgers University, where she determined the three-dimensional X-ray crystallographic structures of human viruses and viral proteins.
PATRICIA (PATTY) MARTIN President and CEO, BioCrossroads
Patricia (Patty) Martin joined BioCrossroads as the president and CEO in July 2019. A former Eli Lilly and Company executive, she was the chief operating officer (COO) of Lilly Diabetes for seven years as well as served as Lilly’s Chief Diversity Officer (CDO) and Chief Alliance Officer (CAO). In her 25-year career at Lilly, she also had leadership roles that included strategy, clinical product development, and investor relations.
Martin’s background is a unique breadth of experience integrating science and business. As COO of Lilly Diabetes, she was part of a leadership team that established a vision and strategy that uniquely addressed the increased prevalence and diverse needs of people living with diabetes. During her tenure, Lilly Diabetes launched an unprecedented six new products in 18 months, increasing sales from $6 billion to $8 billion. As CAO, she spearheaded collaborative efforts to ensure the success of Lilly’s partnerships and facilitated cross-functional and cross-disciplinary cooperation to deliver results.
Martin serves on the board of directors of CareSource, Inc. and UltiMed, Inc.
Actively involved in Indianapolis and national non-profit organizations, she is currently a member of the Indiana University Women’s Philanthropy Leadership Council; member of the board of trustees of the Christian Theological Seminary; the Dean’s Advisory Council for the Indiana University Kelley School of Business; and was the board chair for the 500 Festival in 2016. She also serves a board member of the Diabetes Patient Advocacy Coalition.
A graduate of Indiana University, Martin also earned her MBA from the Harvard School of Business.
KETAN PARANJAPE Vice President of Diagnostics Information Solutions, Roche Diagnostics
Ketan is the VP of Diagnostics Information Solutions (DIS) Commercial Operations at Roche. The DIS business aims to harness the power of data, diagnostics and other critical information to support better clinical decisions.
Prior to this role, Ketan was a managing Director at Health2047 and VP at Akiri Networks, couple of silicon-valley startups funded by the American Medical Association and Celegene, developing and commercialization solutions for data liquidity, chronic care, productivity, security, and payments.
As the former VP and GM of Health and Life Sciences at Intel Corporation, Ketan is a global health and life sciences business leader with a track record of identifying new businesses, developing products and solutions, sales and marketing, developing partnerships, and delivering exceptional financial results. During his 19-year tenure at Intel, Ketan served as Head of Product and Head of ENgineering on a variety of cutting edge technologies along with being the Technical Advisor and Chief of Staff to the Intel Chief Technology Officer. He has been a member of the US Health IT Standards Committee Precision Medicine Task Force, AAAS-FBI-UNICRI Project on Life Sciences and National and Transnational Security, International Telecommunication Union’s Global Cybersecurity Working Group and World Health Organization’s Experts Working Groups on eHealth.
Ketan holds MS degrees in Electrical Engineering and Computer Sciences from the University of Wisconsin and an MBA from the University of Oregon, where he was the class valedictorian. He also completed the Stanford Executive Program as well as coursework in Healthcare Management at the Harvard School of Public Health. He is an Honorary Research Fellow at the Imperial College London and Technical Advisor in Artificial Intelligence at Lee Kong Chian School of Medicine Singapore. Ketan is a certified Paramedic and reside in Indianapolis, IN with his wife and son.
Dan Peterson is Vice President, Industry & Government Affairs for Cook Group Incorporated based in Bloomington, Indiana. Since joining Cook in 1989, Peterson has held a variety of leadership roles in the areas of operations, finance, accounting and human resources. His current responsibilities involve industry, government and external affairs. Peterson’s primary areas of focus center on policies and programs in healthcare delivery as well as education, economic and workforce development.
He earned a BS in Biology from Indiana University in 1984 and an MBA in Finance also from Indiana University in 1989.
Peterson serves on the Board of Directors for a variety of organizations throughout Indiana including BioCrossroads, Indiana Health Industry Forum, the Regional Opportunities Initiative, Inc., and the Bloomington Economic Development Corporation. Peterson also serves as chairman of the South Central Regional Board of Indiana University Health, and is one of the founding board members for the Indiana Bioscience Research Institute. Dan serves as a commission member of the Indiana Commission for Higher Education and is the immediate past chairman.
Since 1963 Cook Group companies are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. Cook Group companies employ more than 12,000 people globally with operations in North America, Europe and Asia-Pacific. Today, Cook manufactures more than 16,000 products that serve more than 40 medical specialties in 135 countries.
JOHN “JJ” SPEGELE PhD Candidate, BioMedical Health Informatics, Indiana University / Vice President, Business Solutions, Covance Central Laboratory Services (CLS)
John “JJ” Spegele has worked in the CRO industry since 2004 in executive roles in both operations (GM) and information technology (VP). Currently, Spegele is a member of the Covance Central Laboratory executive team serving as the VP for Business Systems and Global Specimen Solutions. In addition to his CRO experience, he has previously worked at Eli Lilly and RWE Technologies based in London, England. He currently serves on the Board of Directors for both BioCrossroads and Kelly Business School Life Sciences.
Spegele is a U.S. Naval Academy graduate and proudly served 21 years in the US Marine Corps. He holds dual master’s degrees in Computer Science and Information Systems and is currently pursuing a PhD in Biomedical Health Informatics at Indiana University.
Dr. Kiersten Stead is a Managing Partner at DCVC Bio. DCVC Bio is an early-staged Venture Capital Fund that supports life science companies that are compute-advantaged: agriculture, therapeutics, and biotechnology. The computational advantage can take many forms from in-silico AI systems, to robotics, and beyond.
Prior to DCVC Bio, Dr. Stead was an Investment Director at Monsanto Growth Ventures (MGV). Dr. Stead has over 15 years of experience in the Biotechnology industry. Prior to joining MGV, Kiersten was on the Burrill & Company Venture Team which invested broadly in Life Sciences and Industrial Biotechnology.
Previously, Kiersten was a Management Consultant specialized in early stage company development. She was a Scientist in Genetics & Molecular Biology at the University of Alberta and at Agriculture and Agri-Food Canada. She holds a Ph.D. in Molecular Biology & Genetics. In addition, she also holds an MBA in Finance from the University of Alberta, where she attended as the AHFMR Scholar. Kiersten is a co-founder of Pairwise, was on the Board of Atomwise, Farmlead, Plant Response Biotech, Vital Fields (acquired), Understory Weather (O) and Blue River Technology (acquired). She currently sits on the boards of a number of portfolio companies. She is also a member of the Investment Committee of Genome Canada GAAP, The Keystone Symposia Scientific Advisory Board, and the EULC, a sport-not-for-profit.
BERK TAS Chief Executive Officer and President, SentiAR
Berk Tas serves as the Chief Executive Officer and President of SentiAR. Berk has led development of emerging technologies and companies in Fortune 500, private equity, venture capital funded and privately held organizations. Prior to joining SentiAR he led the development of a novel Trans-aortic Valve Replacement technology into CE Mark studies at HLT Medical. In 2016, he played an integral role in the acquisition of Sensium, Oxford UK, a novel wireless monitoring technology.
Prior to that he served in various leadership roles at Sunshine Heart developing a first of its kind, heart failure therapy and at Boston Scientific developing several novel therapies and technologies focused in Cardiac Rhythm Management. He holds an MBA from the Carlson School of Business at the University of Minnesota and a BS in Electrical Engineering and Physics from the School of Engineering at St Thomas University.
Simon Tripp is a Principal and Senior Director at TEConomy and was formerly Senior Director of the Battelle Technology Partnership Practice. At TEConomy, Tripp is responsible for project team leadership in technology-based economic development, regional economic strategies and impact assessment. Tripp has led major technology-based economic development projects in states and regions throughout the U.S. and internationally. Prior to joining Battelle and then TEConomy, Tripp served as Senior Partner of Impact Economics, LP a consultancy providing specialized economic impact and strategic planning services for government, higher education institutions and bioscience organizations. Tripp founded Impact Economics in 2000, following on from his position as co-founder, President and CEO of the Pittsburgh-based research and planning company Tripp Umbach & Associates, Inc. (which he led from 1991 through 2000). A native of the United Kingdom, Tripp has also held positions as a Director of U.S. Operations for the British Government’s West Midlands Development Agency and as Vice President of North American Business Development for the Welsh Development Agency. He received his M.A. in Geography (Regional Economics) at West Virginia University where he worked at the Regional Research Institute, and his B.A. from the University of Portsmouth in the United Kingdom.
JOSHUA R. VEST, PhD, MPH Research Scientist, Center for Biomedical Informatics, Regenstrief Institute, Inc.; Associate Professor of Health Policy & Management, Indiana University Richard M. Fairbanks School of Public Health at IUPUI; Director, Center for Health Policy, Indiana University Richard M. Fairbanks School of Public Health at IUPUI
His work is focused on the adoption, utilization, impact, and policy issues of technologies that facilitate the sharing of patient information between different organizations. His work with health information exchange has ranged from organizational adoption and strategy to impact on outcomes such as readmission rates, repeat imaging, and costs. His 75+ peer-reviewed publications have employed a variety of research techniques from large-scale database analyses, to geographical information system mapping, to survey research, to qualitative focus groups and interviews. As a former local public health practitioner, Dr. Vest has a particular interest in effective public health information systems.
Dr. Vest is also Director of the Center for Health Policy at the IU Richard M. Fairbanks School of Public Health at IUPUI, the hub of health policy and management of scholarly activity in Indiana with the mission of generating evidence to inform decision making for Indiana and beyond. The Center for Health Policy conducts rigorous research and evaluation on health system performance with a specific focus on: population health and analytics; substance abuse and mental health services; and public health systems and services research.
CHRISTINA BODUROW, PhD Vice President, Global Regulatory Affairs, Data Sciences, Safety and Regulatory, IQVIA
Dr. Christina Bodurow is Vice-President, Global Regulatory Affairs, in the Data Sciences, Safety and Regulatory Division at IQVIA. Chris’ prior experience includes 33 years at Eli Lilly and Company. She held responsibilities including Senior Director of External Sourcing in the Medicines Development Unit (MDU), Chief Operating Officer (COO), Product Research & Development (CMC component of LRL), as well as global R&D operations leader for the Prozac and Xigris Product Teams. Dr. Bodurow has served in a number of professional and community volunteer roles, including on the Board of Directors of the American Chemical Society, the Chemistry Advisory Board for Princeton Chemistry, as well as a member of the Board of Directors of the Indianapolis Symphony Orchestra. Dr. Bodurow received her Bachelor’s in Science from Kalamazoo College, and her Ph.D. in Organic Chemistry from Princeton University. She is a scientific advisor for the Indiana Life Sciences Summit.
Dr. Malaz Boustani is a senior health services neuroscientist with extensive experience in conducting pragmatic and complex clinical trials with a main focus on the impact of acute and chronic illness on brain health. Dr. Boustani is the Founding Director of the Sandra Eskenazi Center for Brain Care Innovation and the Chief Innovation and Implementation Officer for Indiana University Center for Health Innovation and Implementation Science. Over the past decade, Dr. Boustani has built a clinical laboratory within two health care systems in Indiana; Indiana University Health, a state wide system that include 18 hospitals; and Eskenazi Health, a safety net health system serving the need of the underprivileged Marion County residents in Indianapolis. He has used this clinical laboratory to train clinical investigators who have successfully received career development awards from the NIH and has developed a graduate certificate in Innovation and Implementation Science to provide the country with transformational agents who are skilled in building learning health care systems (www.hii.iu.edu). He further used the above clinical laboratory to lead the execution of numerous clinical research studies funded by the NIH, AHRQ, and CMS (R01AG040220; R01AG029884; R01HS0884; R01HS019818;R01AG034205; K23043476; 1C1CMS331000-01-00). Dr. Boustani was the PI of NIA funded two pragmatic randomized controlled trials (R01AG029884) that have enrolled more than 500 subjects from three hospitals in Indianapolis. These two trials evaluated the impact of multicomponent pharmacological management programs on delirium duration and severity among patients admitted to the ICU.
Dr. Callahan conducts observational and interventional research to improve the care of older adults with dementia and depression in primary care settings. This work includes clinical trials exploring new models of care seeking to improve the care of vulnerable elders. These models increasingly focus on the integration of family, community, and medical services. He continues to study new approaches to implement care models into routine clinical practice. In 1999-2000, he was a Visiting Scholar in the History and Psychopathology Research Program in the Department of Psychiatry at Cambridge University in the United Kingdom. During this sabbatical, he co-authored the book “Reinventing Depression: A History of the Treatment of Depression in Primary Care” (Oxford University Press). He received the Midcareer Research Mentorship Award from the Society of General Internal Medicine in 2006 and the Edward Henderson Award from the American Geriatrics Society in 2016.
Carmel Egan, PhD, is the Associate Dean of Research Affairs at the Indiana University School of Medicine (IUSM), the Operations Director of Indiana University’s Precision Health Initiative, and the Chief Operating Officer for the Indiana Clinical and Translational Sciences Institute (CTSI). Prior to joining IUSM in 2016, Dr. Egan was most recently the Vice President, Medicines Development Unit at Lilly, and has held a series of senior leadership positions at Lilly. She has served as Vice President of special Alzheimer’s disease initiatives in Lilly’s Biomedicines Business Unit and previously as Vice President of the Portfolio and Project Management group within Lilly Research Laboratories.
The Precision Health Initiative, funded in part by the IU Grand Challenges Initiative, is a $120 million multi-campus effort to incorporate the genetic, developmental, behavioral and environmental factors that contribute to an individual’s health and develop highly targeted therapies that will improve the well-being of both individuals and the community.
Dr. Egan, received her PhD in chemistry from the University College Dublin in Ireland prior to joining Lilly. She is married to Gerard Carthy and has two sons, Gerard and Kevin.
ROBERT P. FRIEDLAND, MD University of Louisville School of Medicine
Robert Paul Friedland (BS, City College of New York 1969; MD, Mount Sinai School of Medicine, New York, 1973) completed a fellowship in brain aging and dementia at the Albert Einstein College of Medicine in New York and worked as Chief Neurologist at the Donner Laboratory, University of California Berkeley. At the National Institute on Aging, NIH he served as Deputy Clinical Director and Chief of the Brain Aging and Dementia Section. Dr Friedland moved to Cleveland in 1990 to be Professor of Neurology, Radiology and Psychiatry at Case Western Reserve University School of Medicine. In 2008 he came to the University of Louisville and became Chairman and Professor of Neurology & Anatomical Sciences and Neurobiology, and the Rudd Chair. He also served as Interim Chair of the Dept. of Neurosurgery and is currently Chief of the Laboratory of Neurogeriatrics at the University of Louisville.
Dr. Friedland’s work has focused on multidisciplinary approaches to neurodegenerative diseases in an effort to: 1) uncover the environmental factors responsible for their development; and 2) develop effective preventive and therapeutic measures. His work has involved studies in the Middle East, Africa and Japan, as well as the USA. Dr. Friedland has authored or coauthored over 220 scientific publications in refereed journals, and his work has been cited over 12,000 times. His current approach to the mechanisms of initiation of neurodegeneration developed from a longstanding interest in the biology of brain aging. Recent research from his lab is focused on human subjects as well as animal models of Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis and frontotemporal lobar degeneration (Pick’s disease). His collaborators include faculty at the University of Louisville in the Departments of Neurology, Anatomical Sciences and Neurobiology, Biochemistry, Oral Immunology, Physiology, Epidemiology and Biostatistics, and the Cancer Center. Research is also underway with colleagues in The United Kingdom and Japan. In 2017 he was appointed Visiting Professor at the Shiga University of Medical Sciences in Otsu, Japan. Dr. Friedland sees patients with a focus on cognitive, behavioral, and geriatric neurology.
GREGORY KNIPP Faculty Director, Purdue Translational Pharmacology CTSI Core Facility, Bindley Biosciences Center
Dr. Knipp has been actively engaged in collaborative research with several investigators focused on drug discovery support and preclinical evaluation. His expertise in the physicochemical and biopharmaceutical preclinical characterization of novel and traditional therapeutic agents. His career began conducting preclinical preformulation studies of new chemical entities and their excipient interactions required for formulation development at Bristol-Myers Squibb. His doctoral research focused on the delineation of the effects of secondary structure and lipophilicity on the passive permeation of oligopeptides across the Caco-2 and Bovine Brain Microvessel endothelial cell lines. He then characterized the role of placental fatty acid transporters, metabolism and their regulation in of fetal essential fatty acid homeostasis in his postdoctoral research. Upon joining Rutgers University in 1999, his academic research program focused on several projects including: delineating passive and transporter mediated nutrient and xenobiotic permeation across the intestine; elucidating the effects of xenobiotics on in vitro and in vivo rat placental and fetal fatty acid homeostasis, particularly in the brain; and performed translational research elucidating the effects of immunosuppressive agents on macrophage atherosclerotic markers expression as a cellular basis for observed clinical outcomes. He joined Purdue in 2006, where he has continued to build upon his previous research interests and established an innovative program aimed at linking permeation across the Blood Brain Barrier to neuroactivity assessment in vitro and has worked collaboratively to perform preformulation development and assessment with several drug discovery colleagues. In addition, he has helped establish and then become the Faculty Director of the Purdue Translational Pharmacology CTSI Core facility in the Bindley Biosciences Center, which houses the Rodent and PigTurn-Culex units. He has received funding for investigating the PK of therapeutic agents in rodents and pigs from several sources including NIH CTSI Pilot Projects, DTRA, TRASK funding for Purdue Intellectual Property development, NIH SBIR funding for establishing the PigTurn facility, NSF funding, and several industrial based grants/contracts, and FDA funding for developing and testing novel pediatric formulations. He has chaired the NICHD-BPCA Pediatric Formulation Initiatives Workshop’s ADME Subsection of the Pediatric Biopharmaceutics Classification System (PBCS) and served on the Advance Knowledge of Ontogeny of Transporters Task Force.
Terri Pascarelli has held Life Science leadership positions for over twenty-five years. She joined AIT Bioscience, LLC as Chief Executive Officer and member of the company’s Board of Directors in January 2015.
Terri’s experience ranges across start-up and Fortune 500 firms. Prior to AIT Bioscience, Terri was Vice President, Client Development at YourEncore in Indianapolis. Previous leadership roles include serving as President and COO of a venture-backed pharmaceutical company and a privately-held medical laboratory company, both based in Indiana. She held leadership roles in strategy, sales/marketing management, managed markets, R&D and commercial operations at Boehringer Ingelheim Pharmaceuticals, Roche Pharmaceuticals and AstraZeneca.
Terri is an active leader who supports BioCrossroads and the Indiana Life Sciences Summit, including serving on the steering committee for the scientific track of the annual conference.
Terri’s leadership helped put AIT Bioscience on Inc. Magazine’s List of Fastest Growing Private Companies two times in recent years, once ranking on the Inc. 500 list and once on the Inc. 5000 list.
Terri was recognized with the 2018 Strategic Transformation Achievement Recognition (STAR) award by the Healthcare Businesswomen’s Association (HBA). This award honors an individual who stands apart as an exemplary role model and has demonstrated a long-term commitment to furthering the HBA’s strategic goals.
Terri was recognized as a 2018 PharmaVOICE 100 most inspiring people in healthcare. Terri has served as a faculty member at the Vanguard Forum in NYC for senior executives advancing into C-suite roles in life sciences firms. Terri is a member of the Strategic Planning Committee of the Women Business Leaders of the U.S. Healthcare Industry (WBL). She earned her BS, Pharmacy from Rutgers University and holds a MBA from Pace University, NY.
Terri is a scientific advisor for the Indiana Life Sciences Summit.
In 2017, Sobol was named to Chicago’s 2017 Jewish 36 under 36 list as well as AARP’s 50+ Innovation Leaders for healthcare. Adam is also active on the American Medical Director Association’s Innovation board.
Sobol earned an undergraduate degree in informatics and a graduate degree in information systems and cybersecurity, both from Indiana University. Based in Chicago, IL, Sobol is an avid rower, tennis player, and cellist.